EVERSANA, the leading provider of global services to the life sciences industry, continues to use proven integrated commercialization strategies driven by cutting-edge technologies and faster, real-time data.
EVERSANA recently introduced NAVLIN by EVERSANA™, a new, comprehensive ecosystem of price and access solutions to help established and emerging pharmaceutical companies navigate global market access complexities. NAVLIN combines best-in-class data, software and insights into an integrated platform, backed by a team of innovative industry experts.
For ecosystem users, NAVLIN provides price and access data to set global pricing strategies and then apply those strategies to proprietary reference pricing, launch sequencing and predictive pricing models to evaluate the impact of their pricing decisions.
Additionally, NAVLIN provides in-depth market research insights into market access all the way through patient access, as well as custom insights leveraging an unmatched panel of industry experts in the medical, pharmaceutical, contracting and hospital systems and pharmacy industries.
EVERSANA also recently announced a strategic partnership with Integra Connect, LLC, designed to support life sciences companies as they develop and commercialize new oncology treatments.
EVERSANA and Integra Connect, the leading provider of value-based, precision medicine technologies and services for specialty care, will contribute market-leading expertise, real-world data and technologies to create a comprehensive longitudinal oncology patient database. Once available, life sciences companies will be able to leverage the database to optimize their decision-making across a product’s entire life cycle.
Takeaway: EVERSANA’s objective is to improve the patient journey with innovative and life-changing therapies when patients need them the most: now